EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
Select your location
Local sites
Dr. Senping Cheng
EY Entrepreneurial Winning Women™ Asia-Pacific Class of 2025
Founder and CEO, Triastek, Greater China
Dr. Senping Cheng is the founder and CEO of Triastek, a company at the forefront of 3D printing pharmaceuticals. Based out of China, Triastek employs more than 100 professionals. The company's proprietary technology is designing transformative medicines, solving complex formulation challenges and accelerating new drug development.
With 14 years of entrepreneurial experience, Dr. Senping founded Pan-Pacific Biopharma in San Francisco in 2010 and Triastek in Nanjing in 2015. Triastek's innovative Melt Extrusion Deposition (MED®) process is revolutionizing medicine development and production. Triastek's achievements include being named a "Technology Pioneer" by the World Economic Forum in 2024 and winning the TCT Health care Application Award in 2023.
Dr. Senping has authored 23 papers and filed 204 patent applications, earning her numerous accolades, such as being named in Forbes' 20 Potential Women in Chinese Business for 2022 and 2023, Forbes' Top 50 Women in Tech in China for 2022, and Fortune China's Most Powerful Women (Future) for 2023 and 2024.
Triastek aspires to become a leading company in intelligent pharmaceuticals. With a business model that spans both the pharmaceutical and technology platforms, Triastek engages in the entire industry service chain, aiming for stable revenue and seeking global partnerships to create a holistic pharmaceutical ecosystem for the future.
Triastek envisions becoming a globally influential enterprise in pharmaceuticals, with pioneering 3D printing technology, revolutionizing medicine and enhancing patient care worldwide.